Catalyst
Key milestones include dose escalation results and interim efficacy data over the 6-year study duration.
Date
June 20, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.